December 23, 2013
BioTime’s (NYSE MKT: BTX) Subsidiary Cell Cure Neurosciences - $1.7 M Grant
December 17, 2013
BioLife Solutions (OTC: BLFS) Covering all the bases to improved shareholder liquidity - My VIEW
December 11, 2013
StemCells, Inc. (STEM), Q3/13 and 9 month results – SELL
December 11, 2013
International Stem (OTC: ISCO) $10.25 M ATM - HOLD
December 2, 2013
Osiris (OSIR) C. Randall Mills steps down as CEO
December 2, 2013
Asterias Biotherapeutics files for offering of 15 M units of common and redemption right
November 21, 2013
The sector has to exorcise the demons to walk the dead
November 16, 2013
Debt is a drag
November 16, 2013
Skin-in-the-game
November 16, 2013
The Tell
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.